Health Catalyst (HCAT) Misses Q4 EPS by 54c, provides guidance

Health Catalyst (NASDAQ: HCAT) reported Q4 EPS of ($0.53), $0.54 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $75.08 million versus the consensus estimate of $73.57 million.

GUIDANCE:

Health Catalyst sees FY2024 revenue of $304-312 million, versus the consensus of $324.4 million. Adjusted EBITDA between $24 million and $26 million.

For earnings history and earnings-related data on Health Catalyst (HCAT) click here.

You May Also Be Interested In

• Medtronic (MDT) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY27 EPS Guidance
• Hawaiian Electric trades at 8.8x P/E, but wildfire risk clouds value case
• Morgan Stanley upgrades Robinhood, sees 43% upside